Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD trial group. Ismail-Beigi F, et al. Lancet. 2010 Aug 7;376(9739):419-30. doi: 10.1016/S0140-6736(10)60576-4. Epub 2010 Jun 30. Lancet. 2010. PMID: 20594588 Free PMC article. Clinical Trial.
Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial.
Taheri H, Chiti H, Reshadmanesh T, Gohari S, Jalilvand A, Arsang-Jang S, Ismail-Beigi F, Ghanbari S, Dadashi M, Asgari A, Mahjani M, Karbalaee-Hasani A, Ahangar H. Taheri H, et al. J Diabetes Metab Disord. 2023 Sep 22;22(2):1723-1730. doi: 10.1007/s40200-023-01305-2. eCollection 2023 Dec. J Diabetes Metab Disord. 2023. PMID: 37975102
The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial.
Gohari S, Reshadmanesh T, Khodabandehloo H, Karbalaee-Hasani A, Ahangar H, Arsang-Jang S, Ismail-Beigi F, Dadashi M, Ghanbari S, Taheri H, Fathi M, Muhammadi MJ, Mahmoodian R, Asgari A, Tayaranian M, Moharrami M, Mahjani M, Ghobadian B, Chiti H, Gohari S. Gohari S, et al. Diabetol Metab Syndr. 2022 Nov 17;14(1):170. doi: 10.1186/s13098-022-00951-5. Diabetol Metab Syndr. 2022. PMID: 36397128 Free PMC article.
Insulin Resistance/Sensitivity Measures as Screening Indicators of Metabolic-Associated Fatty Liver Disease and Liver Fibrosis.
Khamseh ME, Malek M, Jahangiri S, Nobarani S, Hekmatdoost A, Salavatizadeh M, Soltanieh S, Chehrehgosha H, Taheri H, Montazeri Z, Attaran F, Ismail-Beigi F, Alaei-Shahmiri F. Khamseh ME, et al. Among authors: ismail beigi f. Dig Dis Sci. 2024 Apr;69(4):1430-1443. doi: 10.1007/s10620-024-08309-9. Epub 2024 Mar 4. Dig Dis Sci. 2024. PMID: 38438774
Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Dehghani M, Sadeghi M, Barzkar F, Maghsoomi Z, Janani L, Motevalian SA, Loke YK, Ismail-Beigi F, Baradaran HR, Khamseh ME. Dehghani M, et al. Among authors: ismail beigi f. Front Endocrinol (Lausanne). 2024 Mar 21;15:1286827. doi: 10.3389/fendo.2024.1286827. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38586456 Free PMC article.
Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Gonzalez JS, Bebu I, Krause-Steinrauf H, Hoogendoorn CJ, Crespo-Ramos G, Presley C, Naik AD, Kuo S, Johnson ML, Wexler D, Crandall JP, Bantle AE, Arends V, Cherrington AL; GRADE Research Group. Gonzalez JS, et al. Diabetes Care. 2024 Apr 1;47(4):610-619. doi: 10.2337/dc23-2459. Diabetes Care. 2024. PMID: 38416773
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
Green JB, Everett BM, Ghosh A, Younes N, Krause-Steinrauf H, Barzilay J, Desouza C, Inzucchi SE, Pokharel Y, Schade D, Scrymgeour A, Tan MH, Utzschneider KM, Mudaliar S; GRADE Study Research Group. Green JB, et al. Circulation. 2024 Mar 26;149(13):993-1003. doi: 10.1161/CIRCULATIONAHA.123.066604. Epub 2024 Feb 12. Circulation. 2024. PMID: 38344820 Clinical Trial.
261 results